Abstract
Oral lorcaserin (BELVIQ®), a selective serotonin 5-HT2C receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes). This article reviews the pharmacological properties, therapeutic efficacy and tolerability of oral lorcaserin in this patient population. In three large randomized, double-blind, multicentre studies, oral lorcaserin was more effective than placebo in the management of obese and overweight adults with or without type 2 diabetes mellitus. Following 12 months’ therapy, significantly higher proportions of lorcaserin than placebo recipients achieved a ≥5 and ≥10 % reduction from baseline in their bodyweight and a significant between-group difference favouring lorcaserin over placebo was observed for the change from baseline in bodyweight. Moreover, among patients who had achieved a ≥5 % reduction in their bodyweight after 12 months’ therapy with lorcaserin, a significantly higher proportion who received lorcaserin for a further 12 months than those who switched to placebo maintained ≥5 % weight loss at 24 months. In general, oral lorcaserin was well tolerated in clinical studies, with hypoglycaemia and headache the most frequently reported adverse events in those with or without type 2 diabetes, respectively. According to a pooled analysis, the risk of US-FDA-defined valvulopathy with lorcaserin is generally low and not statistically significantly different from placebo. From these and other data, the FDA has concluded that lorcaserin is unlikely to elevate the risk of valvulopathy.
Similar content being viewed by others
References
Bays H. Phentermine, topiramate and their combination for the treatment of adiposopathy (‘sick fat’) and metabolic disease. Expert Rev Cardiovasc Ther. 2010;8(12):1777–801.
Bays HE. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert Rev Cardiovasc Ther. 2011;9(3):265–77.
Halford JCG, Boyland EJ, Lawton CL, et al. Serotonergic anti-obesity agents: past experience and future prospects. Drugs. 2011;71(17):2247–55.
Bai B, Wang Y. The use of lorcaserin in the management of obesity: a critical appraisal. Drug Des Dev Ther. 2011;5:1–7.
Eisai Inc. BELVIQ (lorcaserin hydrochloride) tablets, for oral use. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf. Accessed 5 Dec 2012.
Martin CK, Redman LM, Zhang J, et al. Lorcaserin, a 5-HT2C receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab. 2011;96(3):837–45.
Coleman E. FDA briefing document. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000SumR.pdf. Accessed 5 Dec 2012.
O’Neil P, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426–36.
Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–77.
Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–56.
Data on file, Eisai Inc., 2013.
Fidler MC, Shazer R, Sanchez M, et al. Lorcaserin, a selective 5-HT2C agonist, evaluated as a weight loss agent in obese and overweight patients with type 2 diabetes treated with sulfonylureas or metformin [abstract no. 1908-P]. Diabetes. 2011;60(Suppl. 1):A515.
Stubbe S, Zhang J, Sanchez M, et al. Comparative efficacy of lorcaserin for weight loss in high risk obese patients and low risk overweight patients [abstract no. 2882-PO]. Diabetes. 2012;61(Suppl. 1):A713–4.
Raether B, Krolikowski J, Sanchez M, et al. Effects of lorcaserin on body composition in the BLOSSOM study of obese and overweight patients [abstract no. 2028-P]. Diabetes. 2012;61(Suppl. 1):A518–9.
Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16(7):777–802.
US Food and Drug Administration. Center for Drug Evaluation and Research. Medical review(s). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000MedR.pdf. Accessed 30 Jan 2013.
Colman E, Golden J, Roberts M, et al. The FDA’s assessment of two drugs for chronic weight management. N Engl J Med. 2012;367(17):1577–9.
Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83(6):897–902.
Arena Pharmaceuticals Inc. Lorcaserin hydrochloride: briefing document for FDA Advisory Committee meeting. 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM303200.pdf. Accessed 27 Feb 2013.
Disclosure
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Additional information
The manuscript was reviewed by: H.E. Bays, Louisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville, KY, USA; E.J. Hendricks, Center for Weight Management, Roseville, CA, USA.
Rights and permissions
About this article
Cite this article
Hoy, S.M. Lorcaserin: A Review of its Use in Chronic Weight Management. Drugs 73, 463–473 (2013). https://doi.org/10.1007/s40265-013-0035-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-013-0035-1